Common Stocks - 96.0%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 1.4%
|
|||
Biotechnology - 1.4%
|
|||
Natera, Inc. (a)
|
500,000
|
27,975,000
|
|
Oxford BioMedica PLC (a)
|
4,000,000
|
8,423,066
|
|
Repligen Corp. (a)(b)
|
257,500
|
40,491,875
|
|
76,889,941
|
|||
Financial Services - 0.0%
|
|||
Specialized Finance - 0.0%
|
|||
Saluda Medical, Inc. warrants 1/20/27 (a)(c)(d)
|
235,185
|
571,500
|
|
Health Care Equipment & Supplies - 50.3%
|
|||
Health Care Equipment - 49.6%
|
|||
Abbott Laboratories
|
2,180,000
|
227,352,200
|
|
Becton, Dickinson & Co.
|
160,000
|
37,788,800
|
|
Boston Scientific Corp. (a)
|
14,000,000
|
782,460,000
|
|
DexCom, Inc. (a)
|
640,000
|
73,932,800
|
|
Edwards Lifesciences Corp. (a)
|
1,400,000
|
94,794,000
|
|
GE Healthcare Holding LLC
|
380,000
|
26,014,800
|
|
Glaukos Corp. (a)
|
1,200,000
|
76,668,000
|
|
Inspire Medical Systems, Inc. (a)
|
690,000
|
100,263,900
|
|
Insulet Corp. (a)
|
660,000
|
124,799,400
|
|
Intuitive Surgical, Inc. (a)
|
700,000
|
217,588,000
|
|
iRhythm Technologies, Inc. (a)
|
75,000
|
6,396,000
|
|
Masimo Corp. (a)(b)
|
1,200,000
|
112,512,000
|
|
Nevro Corp. (a)
|
1,000,000
|
17,320,000
|
|
Novocure Ltd. (a)
|
807,700
|
9,910,479
|
|
Outset Medical, Inc. (a)(b)
|
1,000,000
|
5,240,000
|
|
Penumbra, Inc. (a)
|
1,080,000
|
239,857,200
|
|
PROCEPT BioRobotics Corp. (a)(b)
|
1,180,000
|
43,742,600
|
|
ResMed, Inc.
|
240,000
|
37,855,200
|
|
Shockwave Medical, Inc. (a)
|
380,000
|
66,329,000
|
|
Stryker Corp.
|
1,250,000
|
370,412,500
|
|
Tandem Diabetes Care, Inc. (a)
|
1,450,700
|
29,362,168
|
|
2,700,599,047
|
|||
Health Care Supplies - 0.7%
|
|||
ICU Medical, Inc. (a)
|
350,000
|
30,716,000
|
|
Lantheus Holdings, Inc. (a)
|
142,241
|
10,187,300
|
|
40,903,300
|
|||
TOTAL HEALTH CARE EQUIPMENT & SUPPLIES
|
2,741,502,347
|
||
Health Care Providers & Services - 2.3%
|
|||
Health Care Services - 2.3%
|
|||
agilon health, Inc. (a)
|
3,750,000
|
39,825,000
|
|
Guardant Health, Inc. (a)
|
400,000
|
10,068,000
|
|
LifeStance Health Group, Inc. (a)(b)
|
7,008,600
|
48,149,082
|
|
Privia Health Group, Inc. (a)
|
1,400,000
|
28,924,000
|
|
126,966,082
|
|||
Health Care Technology - 4.1%
|
|||
Health Care Technology - 4.1%
|
|||
DNA Script (a)(c)(d)
|
1,220
|
324,835
|
|
DNA Script (a)(c)(d)
|
4,668
|
1,243,248
|
|
Doximity, Inc. (a)(b)
|
500,000
|
11,625,000
|
|
Evolent Health, Inc.
|
1,003,500
|
27,897,300
|
|
Evolent Health, Inc. (a)
|
900,000
|
25,020,000
|
|
Phreesia, Inc. (a)
|
1,900,000
|
29,279,000
|
|
Veeva Systems, Inc. Class A (a)
|
720,000
|
125,503,200
|
|
220,892,583
|
|||
Life Sciences Tools & Services - 37.9%
|
|||
Life Sciences Tools & Services - 37.9%
|
|||
10X Genomics, Inc. (a)(b)
|
1,871,359
|
81,441,544
|
|
10X Genomics, Inc. Class B (a)(e)
|
392,772
|
17,093,437
|
|
Bio-Techne Corp.
|
150,000
|
9,435,000
|
|
Bruker Corp.
|
1,450,000
|
94,380,500
|
|
Danaher Corp.
|
3,590,000
|
801,682,898
|
|
Gerresheimer AG
|
180,000
|
17,016,521
|
|
IQVIA Holdings, Inc. (a)
|
760,000
|
162,716,000
|
|
Lonza Group AG
|
70,000
|
27,098,480
|
|
Pacific Biosciences of California, Inc. (a)(b)
|
690,000
|
5,851,200
|
|
Sartorius Stedim Biotech
|
100,000
|
22,466,640
|
|
Seer, Inc. (a)
|
2,800,000
|
4,508,000
|
|
Thermo Fisher Scientific, Inc.
|
1,515,000
|
751,076,400
|
|
West Pharmaceutical Services, Inc.
|
190,000
|
66,644,400
|
|
2,061,411,020
|
|||
TOTAL COMMON STOCKS
(Cost $3,385,229,206)
|
5,228,233,473
|
||
Convertible Preferred Stocks - 3.2%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 1.0%
|
|||
Biotechnology - 1.0%
|
|||
Asimov, Inc. Series B (a)(c)(d)
|
97,985
|
4,109,491
|
|
Caris Life Sciences, Inc. Series D (a)(c)(d)
|
2,803,935
|
9,224,946
|
|
Element Biosciences, Inc. Series B (a)(c)(d)
|
2,385,223
|
33,369,270
|
|
ElevateBio LLC Series C (a)(c)(d)
|
214,700
|
646,247
|
|
Inscripta, Inc. Series D (a)(c)(d)
|
3,938,731
|
10,122,539
|
|
57,472,493
|
|||
Financial Services - 0.3%
|
|||
Specialized Finance - 0.3%
|
|||
Saluda Medical, Inc. Series D (c)(d)
|
1,567,904
|
17,607,562
|
|
Health Care Equipment & Supplies - 0.2%
|
|||
Health Care Supplies - 0.2%
|
|||
Kardium, Inc. Series D6 (a)(c)(d)
|
13,783,189
|
12,818,366
|
|
Health Care Providers & Services - 0.3%
|
|||
Health Care Services - 0.3%
|
|||
Conformal Medical, Inc.:
|
|||
Series C (a)(c)(d)
|
2,605,625
|
10,396,444
|
|
Series D (c)(d)
|
525,299
|
2,442,640
|
|
dMed Biopharmaceutical Co. Ltd. Series C (a)(c)(d)
|
309,255
|
1,824,605
|
|
14,663,689
|
|||
Health Care Technology - 0.8%
|
|||
Health Care Technology - 0.8%
|
|||
Aledade, Inc.:
|
|||
Series B1 (a)(c)(d)
|
175,232
|
8,298,988
|
|
Series E1 (a)(c)(d)
|
58,567
|
2,773,733
|
|
DNA Script:
|
|||
Series B (a)(c)(d)
|
59
|
16,258
|
|
Series C (a)(c)(d)
|
28,249
|
12,431,835
|
|
Omada Health, Inc. Series E (a)(c)(d)
|
2,182,939
|
8,469,803
|
|
PrognomIQ, Inc.:
|
|||
Series A5 (a)(c)(d)
|
833,333
|
1,274,999
|
|
Series B (a)(c)(d)
|
2,735,093
|
6,044,556
|
|
Series C (a)(c)(d)
|
752,098
|
1,910,329
|
|
41,220,501
|
|||
Pharmaceuticals - 0.1%
|
|||
Pharmaceuticals - 0.1%
|
|||
Galvanize Therapeutics Series B (a)(c)(d)
|
3,641,139
|
5,061,183
|
|
Textiles, Apparel & Luxury Goods - 0.5%
|
|||
Textiles - 0.5%
|
|||
Freenome, Inc.:
|
|||
Series C (a)(c)(d)
|
2,268,156
|
15,536,869
|
|
Series D (a)(c)(d)
|
1,325,855
|
9,585,932
|
|
25,122,801
|
|||
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $201,503,739)
|
173,966,595
|
||
Preferred Securities - 0.3%
|
|||
Principal
Amount (f)
|
Value ($)
|
||
Health Care Equipment & Supplies - 0.3%
|
|||
Health Care Supplies - 0.3%
|
|||
Kardium, Inc. 0% (c)(d)(g)
(Cost $19,551,861)
|
19,551,861
|
17,889,953
|
|
Money Market Funds - 2.2%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 5.40% (h)
|
25,560,640
|
25,565,752
|
|
Fidelity Securities Lending Cash Central Fund 5.39% (h)(i)
|
94,612,367
|
94,621,828
|
|
TOTAL MONEY MARKET FUNDS
(Cost $120,187,580)
|
120,187,580
|
||
TOTAL INVESTMENT IN SECURITIES - 101.7%
(Cost $3,726,472,386)
|
5,540,277,601
|
NET OTHER ASSETS (LIABILITIES) - (1.7)%
|
(93,849,204)
|
NET ASSETS - 100.0%
|
5,446,428,397
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $193,996,131 or 3.6% of net assets.
|
(d)
|
Level 3 security
|
(e)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $17,093,437 or 0.3% of net assets.
|
(f)
|
Amount is stated in United States dollars unless otherwise noted.
|
(g)
|
Security is perpetual in nature with no stated maturity date.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Aledade, Inc. Series B1
|
5/07/21
|
6,709,756
|
Aledade, Inc. Series E1
|
5/20/22
|
2,917,480
|
Asimov, Inc. Series B
|
10/29/21
|
9,081,318
|
Caris Life Sciences, Inc. Series D
|
5/11/21
|
22,711,874
|
Conformal Medical, Inc. Series C
|
7/24/20
|
9,554,996
|
Conformal Medical, Inc. Series D
|
5/26/23
|
2,668,340
|
dMed Biopharmaceutical Co. Ltd. Series C
|
12/01/20
|
4,392,395
|
DNA Script
|
12/17/21
|
4,714,776
|
DNA Script Series B
|
12/17/21
|
47,244
|
DNA Script Series C
|
10/01/21
|
24,572,393
|
Element Biosciences, Inc. Series B
|
12/13/19
|
12,500,000
|
ElevateBio LLC Series C
|
3/09/21
|
900,667
|
Freenome, Inc. Series C
|
8/14/20
|
14,999,996
|
Freenome, Inc. Series D
|
11/22/21
|
9,999,996
|
Galvanize Therapeutics Series B
|
3/29/22
|
6,303,849
|
Inscripta, Inc. Series D
|
11/13/20
|
18,000,001
|
Kardium, Inc. Series D6
|
12/30/20
|
14,001,515
|
Kardium, Inc. 0%
|
12/30/20
|
19,551,861
|
Omada Health, Inc. Series E
|
12/22/21
|
13,087,156
|
PrognomIQ, Inc. Series A5
|
8/20/20
|
503,333
|
PrognomIQ, Inc. Series B
|
9/11/20
|
6,249,999
|
PrognomIQ, Inc. Series C
|
2/16/22
|
2,301,420
|
Saluda Medical, Inc. warrants 1/20/27
|
1/20/22
|
0
|
Saluda Medical, Inc. Series D
|
1/20/22
|
20,000,011
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 5.40%
|
12,569,252
|
904,586,420
|
891,589,920
|
849,489
|
-
|
-
|
25,565,752
|
0.1%
|
Fidelity Securities Lending Cash Central Fund 5.39%
|
104,979,490
|
1,045,226,951
|
1,055,584,613
|
229,818
|
-
|
-
|
94,621,828
|
0.4%
|
Total
|
117,548,742
|
1,949,813,371
|
1,947,174,533
|
1,079,307
|
-
|
-
|
120,187,580
|
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Nevro Corp.
|
62,880,000
|
3,049,788
|
29,080,318
|
-
|
(46,817,463)
|
27,287,993
|
-
|
Total
|
62,880,000
|
3,049,788
|
29,080,318
|
-
|
(46,817,463)
|
27,287,993
|
-
|